Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Bruzzese, F ^a   Pucci, B ^a   Milone, M R ^a   Ciardiello, C ^a   Franco, R ^a   Chianese, M I ^a   Rocco, M ^a   Di Gennaro, E ^a   Leone, A ^a   Luciano, A ^a   Arra, C ^a   Santini, D ^b   Caraglia, M ^c   Budillon, A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Multiple myeloma; P38 MAPK; Panobinostat; Prostate cancer; Zoledronic acid

Indexed keywords

MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38; PANOBINOSTAT; REACTIVE OXYGEN METABOLITE; SQUALENE SYNTHASE; ZOLEDRONIC ACID;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; HYDROXAMIC ACIDS; IMIDAZOLES; INDOLES; MALE; MEVALONIC ACID; MICE; MICE, NUDE; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887422155     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.406     Document Type: Article

References (45)

1. Mahon KL, Henshall SM, Sutherland RL, Horvath LG. Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer 2011; 18: R103–R123.
2. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011; 103: 1665–1675.
3. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122: 3456–3463.
4. Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012; 104: 1059–1067.
5. Anderson KC. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 2012; 30: 445–452.
6. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879–882.
7. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006; 13: 7–26.
8. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679–691.
9. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396–1405.
10. Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398–405.
11. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989–1999.
12. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011; 49: 34–41.
13. van de Donk NW, Lokhorst HM, Nijhuis EH, Kamphuis MM, Bloem AC. Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clin Cancer Res 2005; 11: 429–439.
14. Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition versus prevention of small GTP-binding proteins. Am J Cancer Res 2011; 1: 542–561.
15. Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 2009; 8: 3075–3087.
16. Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, Subbarayan PR et al. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther 2009; 8: 782–791.
17. Di Gennaro E, Piro G, Chianese MI, Franco R, Di Cintio A, Moccia T et al. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. Br J Cancer 2010; 103: 1680–1691.
18. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011; 226: 2378–2390.
19. Bianchi L, Bruzzese F, Leone A, Gagliardi A, Puglia M, Di Gennaro E et al. Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells. Proteomics 2011; 11: 3725–3742.
20. Budillon A, Bruzzese F, Di Gennaro E. Histone deacetylase inhibitors in cancer therapy. Atta-ur-Rahman, M. Iqbal Choudhary (eds), Frontiers in Anti-Cancer Drug Discovery 2010; Bentham Science: The Netherlands. 978-1-60805-161-8.
21. Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA et al. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 2013; 37: 829–837.
22. Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010; 66: 181–189.
23. Kaizu KNH, Yata K, Otsuki T, Sugihara T, Amagasa T, Sato Y. Comparative genomic hybridization detected nonrandom chromosomal gains and losses in three pairs of sister myeloma cell lines establisced from bone marrow-and pleural effusion cells from the same patient. Oral Med Pathol 2004; 9: 103–111.
24. Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S et al. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis 2013; 4: e641.
25. Sinisi AA, Chieffi P, Pasquali D, Kisslinger A, Staibano S, Bellastella A et al. EPN: a novel epithelial cell line derived from human prostate tissue. In Vitro Cell Dev Biol Anim 2002; 38: 165–172.
26. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999; 56: 131–140.
27. Sonnemann J, Bumbul B, Beck JF. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther 2007; 6: 2976–2984.
28. Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Eur J Pharmacol 2007; 570: 27–37.
29. Kubo T, Shimose S, Matsuo T, Sakai A, Ochi M. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells. Cancer Chemother Pharmacol 2008; 62: 111–116.
30. Morii T, Ohtsuka K, Ohnishi H, Mochizuki K, Satomi K. Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid. Anticancer Res 2010; 30: 3565–3571.
31. Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T et al. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 2008; 14: 3589–3597.
32. Skerjanec A, Berenson J, Hsu C, Major P, Miller WH Jr., Ravera C et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003; 43: 154–162.
33. De Luca A, Lamura L, Gallo M, Daniele G, D’Alessio A, Giordano P et al. Pharmacokinetic evaluation of zoledronic acid. Expert Opin Drug Metab Toxicol 2011; 7: 911–918.
34. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008; 100: 1167–1178.
35. Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph þ leukemia activity of imatinib mesylate. Blood 2003; 102: 2229–2235.
36. Caraglia M, Marra M, Leonetti C, Meo G, D’Alessandro AM, Baldi A et al. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol 2007; 211: 533–543.
37. Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR et al. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 2005; 12: 1051–1058.
38. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833–10838.
39. Dai YS, Xu J, Molkentin JD. The DnaJ-related factor Mrj interacts with nuclear factor of activated T cells c3 and mediates transcriptional repression through class II histone deacetylase recruitment. Mol Cell Biol 2005; 25: 9936–9948.
40. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 673–678.
41. Koto K, Murata H, Kimura S, Sawai Y, Horie N, Matsui T et al. Zoledronic acid significantly enhances radiationinduced apoptosis against human fibrosarcoma cells by inhibiting radioadaptive signaling. Int J Oncol 2013; 42: 525–534.
42. Qi XF, Zheng L, Lee KJ, Kim DH, Kim CS, Cai DQ et al. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis 2013; 4: e518.
43. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007; 1773: 1358–1375.
44. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537–549.
45. Khan AQ, Khan R, Qamar W, Lateef A, Rehman MU, Tahir M et al. Geraniol attenuates 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced oxidative stress and inflammation in mouse skin: Possible role of p38 MAP Kinase and NF-kappaB. Exp Mol Pathol 2013; 94: 419–429.